AOD 9604 vs Frag 176-191: compare structure, stability, research dosing, and FDA status of these two hGH-derived peptides in this balanced guide.
AOD 9604 and Frag 176-191 are both synthetic peptides derived from the C-terminal end of human growth hormone (hGH), and both are studied for their effects on fat metabolism. The key difference is that AOD 9604 is a modified, more stable version of the hGH fragment 177-191 with an added tyrosine, while Frag 176-191 is the native, unmodified fragment. Neither peptide is FDA-approved for human use in the United States.
What Are AOD 9604 and Frag 176-191?
AOD 9604
AOD 9604 is a 16-amino-acid peptide that corresponds to a modified piece of hGH. Researchers engineered it by taking the fat-burning region of hGH (residues 177-191) and adding a tyrosine at the N-terminus to improve stability. This modification allows AOD 9604 to resist enzymatic breakdown better than the native fragment.
AOD 9604 was studied in human clinical trials for obesity in the 2000s. The trials showed modest weight loss, but the results were not strong enough for regulatory approval. AOD 9604 is not approved by the FDA for any human use. It is also on the World Anti-Doping Agency (WADA) prohibited list.
HGH Frag 176-191
HGH Frag 176-191 is the natural C-terminal fragment of human growth hormone, consisting of amino acids 176 through 191. It contains the region of hGH that stimulates lipolysis (the breakdown of fat) and inhibits lipogenesis (the formation of fat). Unlike full hGH, Frag 176-191 does not appear to raise IGF-1 levels or affect blood sugar significantly in research settings.
HGH Frag 176-191 has been studied mainly in animal and in vitro models. Human data are limited compared with AOD 9604. Like AOD 9604, HGH Frag 176-191 is not FDA-approved for human use and is banned by WADA.
Key Differences Between AOD 9604 and Frag 176-191
When people search for aod 9604 vs hgh frag 176-191, they are comparing a stabilized analog with its native parent fragment. Whether you write it as hgh fragment 176-191 vs aod 9604 or the other way around, the core comparison stays the same. The table below summarizes the main differences.
| Feature | AOD 9604 | HGH Frag 176-191 |
|---|---|---|
| Structure | Modified hGH 177-191 with added tyrosine | Native hGH 176-191 |
| Stability | More resistant to enzymatic degradation | Less stable, shorter half-life |
| Human clinical data | Phase II/III obesity trials | Limited human data |
| FDA status | Not approved | Not approved |
| WADA status | Prohibited | Prohibited |
| Typical research dose | 250–500 mcg per day | 250–500 mcg per day (some protocols up to 1000 mcg) |
AOD 9604 is essentially a stabilized version of HGH Frag 176-191. Both target the same fat-metabolism pathways, but AOD 9604 has better stability and more human data. Neither peptide is a proven weight-loss treatment.
Research and Clinical Evidence
AOD 9604 has been tested in human trials for obesity and metabolic syndrome. Those studies found some reduction in body fat, but the effects were modest and not consistent enough to win FDA approval. AOD 9604 has also been explored for osteoarthritis, but the evidence is preliminary.
HGH Frag 176-191 has far less human research. Most studies are in rodents or cell cultures, where the peptide stimulates fat breakdown. There is no large, randomized human trial showing that HGH Frag 176-191 causes meaningful weight loss in people.
Both peptides are sold online as research chemicals. The FDA has warned consumers about products claiming to contain AOD 9604, noting that the ingredient is not approved for use in dietary supplements. No peptide is a substitute for medical care, and anyone considering peptide use should talk to a healthcare professional.
How AOD 9604 Compares to Other Peptides and Drugs
A common question is aod 9604 vs tesamorelin, but the two work very differently. Tesamorelin is an FDA-approved growth hormone-releasing hormone (GHRH) analog used for HIV-associated lipodystrophy. Tesamorelin raises growth hormone and IGF-1 levels, while AOD 9604 is designed to avoid those effects.
Researchers also look at aod 9604 vs mots-c when studying metabolic peptides. MOTS-c is a mitochondrial-derived peptide that influences insulin sensitivity and energy use. AOD 9604 acts on fat cells directly, so the mechanisms are not the same.
For growth hormone release, aod-9604 vs cjc-1295 ipamorelin is a frequent comparison. CJC-1295 and ipamorelin are secretagogues that stimulate the pituitary to release more growth hormone. AOD 9604 does not raise growth hormone; it is a fragment that targets fat metabolism.
Newer obesity drugs like retatrutide belong to an entirely different class (GLP-1/GIP/glucagon receptor agonists). AOD 9604 is not a GLP-1 drug and should not be confused with prescription weight-loss medications.
Safety, Legal Status, and What to Know
AOD 9604 is not FDA-approved for human use in the United States. HGH Frag 176-191 is also not FDA-approved. Both are prohibited by WADA for athletes in any sport.
Common side effects reported in research settings include injection site reactions, headache, and nausea. Long-term safety data are lacking for both peptides. Because these products are often sold as unapproved research chemicals, purity and dosing can be unreliable.
It is important to consult a licensed healthcare provider before using any peptide. Self-treating with unapproved substances carries legal and health risks. No peptide should replace proven strategies like diet, exercise, and FDA-approved medications when appropriate.
Bottom Line
AOD 9604 and Frag 176-191 are closely related peptides that target the same fat-metabolism region of human growth hormone. AOD 9604 is the more stable, better-studied version, but neither is FDA-approved for human use. Research on both is ongoing, and current evidence does not support them as safe or effective weight-loss treatments.
Frequently Asked Questions
Is AOD 9604 the same as Frag 176-191?
They are closely related but not identical. AOD 9604 is a modified version of hGH 177-191 with an added tyrosine, while Frag 176-191 is the native fragment. Both target the same fat-metabolism region of hGH.
Which is stronger, AOD 9604 or Frag 176-191?
There is no reliable head-to-head human study comparing the two. AOD 9604 has more clinical trial data and is more stable, but neither is FDA-approved. Potency claims are not supported by rigorous comparative research.
Is AOD 9604 FDA-approved?
No, AOD 9604 is not FDA-approved for any human use. It has been studied in clinical trials for obesity, but it is not an approved drug. It is also prohibited by WADA for athletes.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.